SecBot SecBot

CSBR

CHAMPIONS ONCOLOGY, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000771856 Biotech & Drug Discovery
$4.82 +0.10 (+2.12%)
Oct 26 4:00 PM ET · prev $4.72
Market cap
$66.3M
Micro cap
1 year
−29.3%
from $6.82 · Oct 27
30 days
−2.2%
from $4.93
52-week range
$4.69–7.80
−38% from high · low Oct 19
Avg volume 20D
9.9K
Sep 30 spike 35.2K
Short interest
71.0K
≈0.5% of shares · +3.6%
Days to cover
4.4
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest BULLISH Champions Oncology reported Q1 FY2027 revenue of $15.2M, up 8.8% YoY, with oncology services margin…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest +3.6% to 71.0K shares. 4.4 days to cover, ≈0.5% of shares.

  • TrendDOWNTREND

    3% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BANK OF AMERICA CORP /DE/DOUBLED214,058$1.3M
NORTHERN TRUST CORPTRIM27,910$171.9K
MORGAN STANLEYADD189,600$1.2M
MILLENNIUM MANAGEMENT LLCTRIM12,635$81.8K
MILLENNIUM MANAGEMENT LLCTRIM24,064$177.4K
MILLENNIUM MANAGEMENT LLCDOUBLED66,613$578.2K
MORGAN STANLEYADD72,900$624.8K
NORTHERN TRUST CORPADD53,994$462.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2025
Recent actions
DateFirmActionRating
Mar 12, 2025Craig-Hallum
MAINTAIN
MAINTAINBuy
Dec 12, 2024Craig-Hallum
MAINTAIN
MAINTAINBuy
Sep 12, 2024Craig-Hallum
UPGRADE
UPGRADEBuy
Mar 13, 2024Craig-Hallum
DOWNGRADE
DOWNGRADEHold
Sep 22, 2023Roth MKM
MAINTAIN
MAINTAINBuy
Mar 15, 2021Roth Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 15, 2026
ACKERMAN JOEL
Director
EXERCISE$111.7K
Jul 16, 2025
Brainin Robert Lawrence
CEO
AWARD$487.5K
Jul 16, 2025
Brainin Robert Lawrence
CEO
AWARD$780.0K
Jul 16, 2025
Brainin Robert Lawrence
CEO
AWARD$1.2M
Jul 16, 2025
Brainin Robert Lawrence
CEO
AWARD$1.8M
Nov 12, 2024
Brainin Robert Lawrence
Director
AWARD$106.9K
Nov 3, 2023
Brainin Robert Lawrence
Director
AWARD$105.1K
Nov 1, 2022
Brainin Robert Lawrence
Director
AWARD$98.9K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
70,961
shares short
+3.6%
vs prior settlement
4.4
days to cover
≈0.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Insider
ACKERMAN JOEL acquired via exercise 69,794 shares
Director @ $1.60 ($111.7K)
Sep 10, 2026 SEC
Champions Oncology reported Q1 FY2027 revenue of $15.2M, up 8.8% YoY, with oncology services margin improving to 51%…
8-K — Impact 6/10
Sep 10, 2026 Earnings calendar
CSBR Q1 2027 Earnings Scheduled — 2026-09-10
Aug 28, 2026 SEC
Champions Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2026 annual meeting. The…
DEFA14A — Impact 2/10
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — DOUBLED
214,058 shares ($1.3M)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — TRIM
27,910 shares ($171.9K)
Jul 16, 2025 Insider
Brainin Robert Lawrence was granted 62,500 shares
CEO @ $7.80 ($487.5K)
Jul 16, 2025 Insider
Brainin Robert Lawrence was granted 100,000 shares
CEO @ $7.80 ($780.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 10, 2026
Earnings date
CSBR Q1 2027 Earnings Scheduled — 2026-09-10
Jul 27, 2026
Earnings date
CSBR Q4 2026 Earnings After Market Close — 2026-07-27
Jul 21, 2026
Earnings date
CSBR Q4 2026 Earnings After Market Close — 2026-07-21
Jul 16, 2026
Earnings date
CSBR Q4 2026 Earnings After Market Close — 2026-07-16
Mar 12, 2026
Earnings date
CSBR Q3 2026 Earnings Scheduled — 2026-03-12

SecBot reports

2 filings · 1 bullish · 0 bearish · 1 neutral
All CSBR filing & press-release reports (2)